Watson launches generic contraceptive
PARSIPPANY, N.J. — Watson Pharmaceuticals has launched a generic version of a contraceptive made by Warner Chilcott, Watson said Monday.
The drug maker announced the launch of chewable norethindrone and ethinyl estradiol tablets in the 0.4-mg/0.035-mg strength and chewable ferrous fumarate tablets in the 75-mg strength.
The product is a generic version of Warner Chilcott’s Femcon Fe, which had sales of about $35 million during the 12-month period ended in July, according to IMS Health.
Lannett receives approval for generic Loxitane
PHILADELPHIA — Lannett has received regulatory approval from the Food and Drug Administration for its version of an antipsychotic treatment.
The drug maker said the FDA approved its abbreviated new drug application for loxapine capsules in the 5-mg, 10-mg, 25-mg and 50-mg strengths. The drug is a generic version of Watson Pharmaceuticals’ Loxitane.
“We have now received five product approvals from the FDA over the last three months,” Lannett president and CEO Arthur Bedrosian said. “Loxapine capsules is an important addition to our product lineup.”
AmerisourceBergen acquires TheraCom from CVS for $250 million
VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.
TheraCom is a provider of commercialization support services to the biotech and pharmaceutical industry, specifically, providing reimbursement and patient access support services, and will join Lash Group as part of AmerisourceBergen Consulting Services.
"The acquisition of TheraCom will significantly increase the size and scope of our consulting services offering and meaningfully expands our reimbursement, adherence and patient access services for pharmaceutical and biotech manufacturers," AmerisourceBergen president and CEO Steven Collis said. "The addition of TheraCom’s capabilities to our market-leading consulting services will provide our manufacturer customers with enhanced solutions to meet the challenges in the changing healthcare landscape, and will help ensure even greater patient access to medication therapies."
Together, Lash Group and TheraCom will offer an extensive platform of services and solutions to support the growing demand for patient access and reimbursement services, and support the need for unique distribution solutions, the company stated.
TheraCom’s annualized revenues are approximately $700 million, the majority of which are provided by the specialized distribution component of the integrated reimbursement support services for certain unique prescription products.